Gridai Technologies's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Gridai Technologies (GRDX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Gridai Technologies vs Its Competitors
- Scale: Gridai Technologies ranks #372 of 544 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
- Peer revenue share: Gridai Technologies accounted for 100.0% of combined revenue among its tracked peer group.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
GRDX Sales vs. its Competitors, Q2 2026
Gridai Technologies generated 100.00 % of the combined sales of its peer group.
Gridai Technologies's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Gridai Technologies Corp | - | - | - | - |
| High-Confidence Competitors (10) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
GRDX Stock Performance relative to its Competitors
GRDX Stock Performance relative to High-Confidence Competitors
GRDX Stock Performance relative to Similar-Size Competitors
Gridai Technologies's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| ANA Therapeutics | Named by the company | 85% |
| Gilead Sciences, Inc. | Named by the company | 85% |
| Neu | Named by the company | 85% |
| AbbVie Inc. | Named by the company | 85% |
| BioNTech SE | Named by the company | 85% |
| Moderna, Inc. | Named by the company | 85% |
| Ridgeback Biotherapeutics | Named by the company | 85% |
| AstraZeneca plc. | Named by the company | 85% |
| Johnson & Johnson | Named by the company | 85% |
| NeuroBo Pharmaceuticals, Inc. | Named by the company | 85% |
| Allergan plc. | Named by the company | 85% |
| Chiesi Farmaceutici S.p.A. | Named by the company | 85% |
| Nestlé S.A. | Named by the company | 85% |
| VIVUS, Inc. | Named by the company | 85% |
| Asymchem Inc. | Named by the company | 85% |
| Merck & Co. Inc. | Named by the company | 85% |
| Pfizer Inc. | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Gridai Technologies's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.